Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent Cancers

Preclinical toxicity evaluation of a novel immunotoxin, D2C7-(scdsFv)-PE38KDEL, administered via intracerebral convection-enhanced delivery in rats

(2016) Xuhui Bao et al.   INVESTIGATIONAL NEW DRUGS

Targeting a Cancer-Specific Epitope of the Epidermal Growth Factor Receptor in Triple-Negative Breast Cancer

(2016) Nathan Simon et al.   JNCI-Journal of the National Cancer Institute

Targeting a Cancer-Specific Epitope of the Epidermal Growth Factor Receptor in Triple-Negative Breast Cancer

(2016) Nathan Simon et al.   JNCI-Journal of the National Cancer Institute

Combinatorial approach to increase efficacy of Cetuximab, Panitumumab and Trastuzumab by dianthin conjugation and co-application of SO1861

(2015) Roger Gilabert-Oriol et al.   BIOCHEMICAL PHARMACOLOGY

A bivalent recombinant immunotoxin with high potency against tumors with EGFR and EGFRvIII expression

(2015) Jie Meng et al.   CANCER BIOLOGY & THERAPY

Elimination of murine and human T-cell epitopes in recombinant immunotoxin eliminates neutralizing and anti-drug antibodies in vivo

(2015) Ronit Mazor et al.   Cellular & Molecular Immunology

A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma

(2015) Manfred Westphal et al.   EUROPEAN JOURNAL OF CANCER

Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities

(2015) Judith Niesen et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

(2015) James Chih-Hsin Yang et al.   LANCET ONCOLOGY

Rare occurrence of EGFRvIII deletion in head and neck squamous cell carcinoma

(2015) Arun Khattri et al.   ORAL ONCOLOGY

NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy

(2015) Wei Wang   Frontiers in Immunology

Photochemical internalization of tumor-targeted protein toxins

(2015) Anette Weyergang et al.   LASERS IN SURGERY AND MEDICINE

Functional Dissection of the Epidermal Growth Factor Receptor Epitopes Targeted by Panitumumab and Cetuximab

(2015) Mareike Voigt et al.   NEOPLASIA

Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen

(2014) Raffit Hassan et al.   CANCER

ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics

(2014) Carlos L. Arteaga et al.   CANCER CELL

Evaluation of the EGFR-Inhibitor Zalutumumab Given With Primary Curative (Chemo)radiation Therapy to Patients With Squamous Cell Carcinoma of the Head and Neck: Results of the DAHANCA 19 Randomized Phase 3 Trial

(2014) J.G. Eriksen et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

In vitro effects and ex vivo binding of an EGFR-specific immunotoxin on rhabdomyosarcoma cells

(2014) Judith Niesen et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Tofacitinib Suppresses Antibody Responses to Protein Therapeutics in Murine Hosts

(2014) M. Onda et al.   JOURNAL OF IMMUNOLOGY

High EGFR gene copy number predicts poor outcome in triple-negative breast cancer

(2014) Heae Surng Park et al.   MODERN PATHOLOGY

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

(2014) D. A. E. Cross et al.   Cancer Discovery

Construction of an Immunotoxin, D2C7-(scdsFv)-PE38KDEL, Targeting EGFRwt and EGFRvIII for Brain Tumor Therapy

(2013) V. Chandramohan et al.   CLINICAL CANCER RESEARCH

The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered

(2013) Hui K. Gan et al.   FEBS Journal

Modified Trastuzumab and Cetuximab Mediate Efficient Toxin Delivery While Retaining Antibody-Dependent Cell-Mediated Cytotoxicity in Target Cells

(2013) Roger Gilabert-Oriol et al.   MOLECULAR PHARMACEUTICS

The quest to overcome resistance to EGFR-targeted therapies in cancer

(2013) Curtis R Chong et al.   NATURE MEDICINE

Targeted Therapy Resistance Mediated by Dynamic Regulation of Extrachromosomal Mutant EGFR DNA

(2013) David A. Nathanson et al.   SCIENCE

Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression

(2013) R. Hassan et al.   Science Translational Medicine

Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC

(2013) A. O. Walter et al.   Cancer Discovery

Immunotoxins: The Role of the Toxin

(2013) Antonella Antignani et al.   Toxins

Diphtheria Toxin-Epidermal Growth Factor Fusion Protein DAB389EGF for the Treatment of Bladder Cancer

(2012) X. Yang et al.   CLINICAL CANCER RESEARCH

Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia

(2012) Robert J. Kreitman et al.   JOURNAL OF CLINICAL ONCOLOGY

Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer

(2012) Kang-Yi Su et al.   JOURNAL OF CLINICAL ONCOLOGY

Saponins modulate the intracellular trafficking of protein toxins

(2012) Alexander Weng et al.   JOURNAL OF CONTROLLED RELEASE

Intracerebral infusion of the bispecific targeted toxin DTATEGF in a mouse xenograft model of a human metastatic non-small cell lung cancer

(2012) Jun Huang et al.   JOURNAL OF NEURO-ONCOLOGY

Targeted tumor therapy by epidermal growth factor appended toxin and purified saponin: An evaluation of toxicity and therapeutic potential in syngeneic tumor bearing mice

(2012) Mayank Thakur et al.   Molecular Oncology

A Novel Anti-Human HB-EGF Monoclonal Antibody with Multiple Antitumor Mechanisms against Ovarian Cancer Cells

(2011) S. Miyamoto et al.   CLINICAL CANCER RESEARCH

A guide to taming a toxin - recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer

(2011) John E. Weldon et al.   FEBS Journal

Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors

(2011) Michael R. Zalutsky et al.   NUCLEAR MEDICINE AND BIOLOGY

Oncogenic EGFR Signaling Activates an mTORC2-NF- B Pathway That Promotes Chemotherapy Resistance

(2011) K. Tanaka et al.   Cancer Discovery

Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic MABS C225 and 425

(2010) Vishal Kamat et al.   CANCER BIOLOGY & THERAPY

Pemetrexed with or without Matuzumab as Second-Line Treatment for Patients with Stage IIIB/IV Non-small Cell Lung Cancer

(2010) Joan H. Schiller et al.   Journal of Thoracic Oncology

Tailored cancer immunotherapy using combinations of chemotherapy and a mixture of antibodies against EGF-receptor ligands

(2010) Moshit Lindzen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy

(2009) E. Martinelli et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

The EGFRvIII variant in glioblastoma multiforme

(2009) Hui K. Gan et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1

(2009) Dale Ding et al.   JOURNAL OF NEURO-ONCOLOGY

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multi-Modality Therapeutics with Potent Anti-Tumor Effects: Photochemical Internalization Enhances Delivery of the Fusion Toxin scFvMEL/rGel

(2009) Pål K. Selbo et al.   PLoS One

Antibodies specifically targeting a locally misfolded region of tumor associated EGFR

(2009) T. P. J. Garrett et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cisplatin-Resistant Neuroblastoma Cells Express Enhanced Levels of Epidermal Growth Factor Receptor (EGFR) and Are Sensitive to Treatment with EGFR-Specific Toxins

(2008) M. Michaelis et al.   CLINICAL CANCER RESEARCH

Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors

(2008) John H. Sampson et al.   NEURO-ONCOLOGY

An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes

(2008) M. Onda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA